Endo Pharma to buy HealthTronics in $223M deal

Endo Pharmaceuticals is planning to buy HealthTronics for $223 million, offering a 34 percent premium for shares that closed at $3.62. If the deal goes through as planned, HealthTronics, which markets urology products and services, will be made a wholly owned subsidiary of Endo, which has been diversifying recently to broaden its revenue sources. "Beyond diversifying our revenue base, the acquisition of HealthTronics further positions Endo as a preferred healthcare provider of multiple medical solutions and delivery mechanisms that help improve patient outcomes in the field of Urology," said Endo CEO Dave Holveck. "This strategic acquisition immediately elevates Endo from a pharmaceutical company to a diversified partner to physicians and payers in the treatment and diagnosis of urological and pain-related conditions. Report (sub. req.)

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.